CAJ | 학술논문

随着肿瘤细胞生物学的进展,已研制出许多针对特异性分子靶向的治疗药物,而且在晚期非细胞肺癌患者的一线和二线治疗中均已显示出较好的疗效,由于老年患者有着生理学、药理学等各方面的特点,对化疗耐受性差,而针对此类患者的分子靶向治疗具有重要临床价值.
수착종류세포생물학적진전,이연제출허다침대특이성분자파향적치료약물,이차재만기비세포폐암환자적일선화이선치료중균이현시출교호적료효,유우노년환자유착생이학、약이학등각방면적특점,대화료내수성차,이침대차류환자적분자파향치료구유중요림상개치.
With the development of tumor cell biology,many targeted therapy drugs that aim specifically to inhibit tumor growth have been developed. Application of targeted drugs as first-line and second-line therapy in patients with advanced non-small cell lung cancer (NSCLC) have acquired exciting curative effect. Molecular targeted therapy for old patients have important clinical values,because old patients have weak toleration to chemotherapy as a result of physical and pharmacological features.